Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation

被引:163
|
作者
King, JT
Tsevat, J
Lave, JR
Roberts, MS
机构
[1] VA Connecticut Healthcare Syst, Neurosurg Sect, West Haven, CT 06516 USA
[2] Yale Univ, Dept Neurosurg, New Haven, CT USA
[3] Univ Cincinnati, Dept Internal Med, Inst Hlth Policy & Hlth Serv Res, Med Ctr, Cincinnati, OH USA
[4] Univ Cincinnati, Ctr Clin Effectiveness, Inst Hlth Policy & Hlth Serv Res, Med Ctr, Cincinnati, OH USA
[5] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA
[6] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA
[7] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA
[8] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[9] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA
关键词
cost-effectiveness analysis; preferences; QALYs; utility; willingness to pay;
D O I
10.1177/0272989X05282640
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. Health-state preferences can be combined with willingness-to-pay (WTP) data to calculate WTP per quality-adjusted life year (QALY). The WTP/QALY ratios provide insight into societal valuations of expenditures for medical interventions. Methods. The authors measured preferences for current health in 3 patient populations (N = 391) using standard gamble, time trade-off, visual analog scale, and WTP then they calculated WTP/QALY ratios. The ratios were compared with several proposed cost/QALY cost-effectiveness ratio thresholds, the value-of-life literature, and with WTP/QALY ratios derived from published preference research. Results. Mean WTP/QALY ratios ranged from $12,500 to $32,200 (2003 $US). All values were below most published cost-effectiveness ratio thresholds, below the ratio from a prototypic medical treatment covered by Medicare (i.e., renal dialysis), and below ratios from the value-of-life literature, The WTP/QALY ratios were similar to those calculated from published preference data for patients with symptomatic menopause, dentofacial deformities, asthma, or dermatologic disorders. Conclusions. WTP/QALY ratios calculated using preference data collected from diverse populations are lower than most proposed thresholds for determining what is "cost-effective," Current proposed cost-effectiveness ratio thresholds may overestimate the willingness of society to pay for medical interventions.
引用
收藏
页码:667 / 677
页数:11
相关论文
共 50 条
  • [21] Assessment of willingness to pay for a quality-adjusted life year in the post COVID-19 pandemic era in Japan
    Kitano, Taito
    Tsuzuki, Shinya
    PUBLIC HEALTH, 2025, 241 : 55 - 59
  • [22] Willingness to pay for a quality-adjusted life year for depressive disorders compared to heart disease based on population preferences
    Ulbrich, Laura
    Kroeger, Christoph
    QUALITY OF LIFE RESEARCH, 2021, 30 (07) : 1985 - 1995
  • [23] Willingness to pay for a quality-adjusted life year for depressive disorders compared to heart disease based on population preferences
    Laura Ulbrich
    Christoph Kröger
    Quality of Life Research, 2021, 30 : 1985 - 1995
  • [24] How much are Americans willing to pay for a quality-adjusted life year?
    Weinstein, Milton C.
    MEDICAL CARE, 2008, 46 (04) : 343 - 345
  • [25] The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature
    Ryen, Linda
    Svensson, Mikael
    HEALTH ECONOMICS, 2015, 24 (10) : 1289 - 1301
  • [26] EXPLORING THE FEASIBILITY OF THE INSTRUMENT USED IN DETERMINATION OF WILLINGNESS-TO-PAY PER QUALITY-ADJUSTED LIFE-YEAR IN MALAYSIA
    Lim, Y. W.
    Shafie, A. A.
    Hassali, M. A. A.
    Chua, G. N.
    VALUE IN HEALTH, 2013, 16 (07) : A596 - A597
  • [27] The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method
    Moradi, Najme
    Rashidian, Arash
    Nosratnejad, Shirin
    Olyaeemanesh, Alireza
    Zanganeh, Marzieh
    Zarei, Leila
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 311 - 319
  • [28] Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis
    Shouki Bazarbashi
    Edward B. De Vol
    Fatma Maraiki
    Ahmed Al-Jedai
    Afshan A. Ali
    Ali M. Alhammad
    Ibrahim A. Aljuffali
    Michael Iskedjian
    PharmacoEconomics - Open, 2020, 4 : 625 - 633
  • [29] The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method
    Najme Moradi
    Arash Rashidian
    Shirin Nosratnejad
    Alireza Olyaeemanesh
    Marzieh Zanganeh
    Leila Zarei
    PharmacoEconomics - Open, 2019, 3 : 311 - 319
  • [30] Societal responsibility and moral hazard: How much are we willing to pay for quality-adjusted life?
    Stevenson, Megan A.
    Abbott, Daniel E.
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 114 (03) : 269 - 274